GLP-1 Microdosing for Inflammation: Early Research Summary

GLP-1 medications are not approved for inflammation, autoimmune conditions, or neurological conditions

Before we go further, this distinction matters. The research covered on this page is early-stage and emerging. FDA-approved uses of GLP-1 medications such as semaglutide and tirzepatide include type 2 diabetes, weight management, and cardiovascular risk reduction, depending on the product.^[2] They are not approved for treating inflammation, autoimmune disease, or related neurological conditions. Most of the data discussed here is observational or from laboratory and animal models, not from large randomized trials in people with these conditions.

If you have an autoimmune condition or inflammatory disease and are interested in GLP-1 medication for that reason, have an honest conversation with a licensed provider about what the current evidence supports and what it does not. This content is for general education and is not medical advice.

Why researchers are looking at GLP-1 for inflammation

GLP-1 receptor agonists act in many parts of the body, not just the gut and pancreas. Part of the research interest comes from reports that GLP-1 receptors are present in some immune cells and in tissues involved in inflammation.

Researchers have reported GLP-1 receptors in:

• Brain tissue (including microglia, which are immune cells in the central nervous system)
• Some immune cells, including certain T cells
• Cardiovascular tissue
• Kidney tissue

Where exactly the receptor is expressed in humans is still debated for some cell types. In laboratory and animal studies, GLP-1 receptor activation has been linked to lower levels of inflammatory signaling molecules, reduced inflammation in colitis models, and better preservation of the gut lining.^[3]

This is why researchers are exploring GLP-1 in conditions driven by chronic, low-grade inflammation. The biological plausibility is there. Whether this effect is clinically useful in humans remains an open question.

What the early research shows

Systemic inflammation: the SELECT trial

The largest human data set comes from the SELECT trial^[1], published in the New England Journal of Medicine in 2023. It enrolled 17,604 adults aged 45 or older with existing cardiovascular disease, a BMI of 27 or higher, and no diabetes, who were randomized to semaglutide 2.4 mg once weekly or placebo. Its main finding was fewer major cardiovascular events (cardiovascular death, heart attack, or stroke) with semaglutide.

The trial also measured high-sensitivity C-reactive protein (hsCRP), a blood marker of systemic inflammation, and reported lower hsCRP levels in the semaglutide group than in the placebo group. People taking semaglutide also lost weight, and weight loss lowers hsCRP on its own, so the trial does not show how much of the change came from the medication itself.

What it means: hsCRP reduction is not the same as treating an inflammatory disease. Lower inflammation markers are linked to cardiovascular health, but reducing hsCRP is not a treatment for rheumatoid arthritis or inflammatory bowel disease. SELECT enrolled people with cardiovascular disease and overweight or obesity, not people selected for active inflammatory or autoimmune conditions. The data tells us that semaglutide lowered an inflammation marker in that population. It does not tell us that semaglutide can treat active autoimmune disease. Results vary, and trial results describe study participants, not what will happen for you.

Rheumatoid arthritis

A 2025 retrospective chart review from UCLA^[2] looked at adults with rheumatoid arthritis (RA) and a BMI of 27 or higher. The 173 people who took semaglutide or tirzepatide had significantly greater reductions in RA disease activity, pain, and body weight over up to one year than the 42 people who were prescribed a GLP-1 medication but did not take it. Nearly one-third of the treated group stopped the medication during the study, most often because of gastrointestinal side effects.

What it means: This is observational data, not a randomized trial. The groups were small and uneven, the people who took the medication may differ in important ways from those who did not, and weight loss may explain part of the improvement. There have been no published randomized, controlled trials of GLP-1 specifically for RA. We cannot claim that GLP-1 is an RA treatment based on these reports.

Inflammatory bowel disease (IBD)

A 2025 review^[3] found that preclinical work shows reduced intestinal inflammation in animal models of colitis, and that early retrospective studies in people with IBD suggest fewer hospitalizations and surgeries, particularly in people with obesity. The same review calls for prospective trials to test safety and effectiveness, and notes open questions about how GLP-1 medications affect the absorption of other drugs and interact with existing IBD treatments. The mechanism is plausible. The evidence is not mature.

Neuroinflammation

GLP-1 medications have been studied in Alzheimer’s disease and Parkinson’s disease, and researchers are interested in other neurological conditions such as multiple sclerosis. The biological argument rests on neuroinflammation (activation of brain immune cells called microglia), which is thought to play a role in these conditions.

The largest results so far are negative. In evoke and evoke+, two phase 3 trials with 3,808 participants published in 2026, oral semaglutide did not slow clinical progression in early Alzheimer’s disease compared with placebo.^[4] Do not treat discussions of GLP-1 for Parkinson’s or Alzheimer’s as established clinical practice.

Psoriasis and other autoimmune skin conditions

Small studies have looked at GLP-1 medications in people with psoriasis, and a 2024 systematic review and meta-analysis pooled the limited data available.^[5] The immune mechanism is plausible. The evidence is limited to small studies, and GLP-1 medications are not approved for psoriasis or any other autoimmune skin condition.

What “microdosing” means in this context

“Microdosing” usually describes using a GLP-1 medication at doses below the standard weight-loss range, most often for weight maintenance after goal weight. Using doses below the labeled range is off-label, which means a prescriber is using clinical judgment outside what the FDA reviewed. Many lower-dose offerings use compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.

Some people interested in GLP-1 for non-weight reasons (like inflammation or autoimmune disease) have asked whether lower doses might provide anti-inflammatory benefit while reducing side effects.

The logic is: if part of the anti-inflammatory effect comes from direct GLP-1 receptor activation in immune cells, then a lower dose might still produce some of that effect, with fewer of the gastrointestinal side effects associated with higher doses.

This is entirely theoretical. There are no clinical trials establishing what dose of GLP-1 is needed to achieve anti-inflammatory effects. The SELECT trial used semaglutide 2.4 mg once weekly. We do not know whether 0.25 mg or 0.5 mg would produce similar reductions in inflammatory markers. We do not know whether lower doses would modify disease in people with active autoimmune conditions.

The major knowledge gaps

Before considering GLP-1 (at any dose) for inflammation or autoimmune conditions, you should understand what we do not know:

Efficacy in human disease: Most inflammation and autoimmune data comes from animal models or observational human studies. We do not have randomized, controlled trial evidence that GLP-1 is effective for any autoimmune condition. This is not evidence that GLP-1 does not work. It is evidence that it has not been tested rigorously in humans yet.

Optimal dosing: The SELECT trial used semaglutide 2.4 mg weekly. We do not have data on whether lower doses produce the same anti-inflammatory effects. The idea that “lower doses might work for inflammation” is based on biological plausibility, not clinical evidence.

Separating weight loss from direct receptor effects: Weight loss itself lowers inflammation. Separating the anti-inflammatory effect of weight loss from any direct effect of GLP-1 receptor activation is methodologically difficult. In people who are losing weight, it is hard to know how much of an hsCRP reduction comes from weight loss versus from the medication itself.

Long-term safety of low-dose indefinite use: Lower-dose use is usually discussed for weight maintenance, not disease treatment. We do not have safety data on using low-dose GLP-1 indefinitely for inflammation or autoimmune disease. Side effects like nausea tend to be dose-dependent, but other safety signals (pancreatitis, thyroid issues, gallbladder problems) might emerge with prolonged use. We simply do not have the data yet.

Whether the effect persists: With weight loss medications, stopping the medication often means regaining weight. With GLP-1 for inflammation, we do not know whether stopping the medication means inflammation returns to baseline, or whether any immune effect persists.

What to check before using a GLP-1 medication for inflammation

No GLP-1 medication is approved for inflammation or autoimmune conditions, and no program’s lower-dose plan has been studied for these uses. If you are weighing GLP-1 for a non-weight reason, these questions help you have a clear conversation with a licensed provider, including the specialist who already manages your condition:

• Evidence: What evidence supports this use for my specific condition, and is it from randomized trials or observational studies?
• Current treatment: How would a GLP-1 medication interact with my current medications, including how it might affect the absorption of drugs I take by mouth?
• Dose and product: What dose would be used, is it on-label or off-label, and would the product be an FDA-approved brand-name medication or a compounded one?
• Monitoring: How would we measure whether it is helping my condition, and what side effects or lab results would make us stop?
• Coordination: Will the prescriber share information with the specialist who treats my autoimmune or inflammatory condition?

Be skeptical of claims that GLP-1 is an established treatment for autoimmune conditions. The current evidence does not support that claim.

Providers may reasonably disagree. Some may feel the research is promising enough to consider GLP-1 for a specific person with a specific condition, especially if there is another reason to use it, such as obesity or type 2 diabetes. Others will not. The right answer depends on your health situation, your current treatments, and the provider’s assessment of the risks and potential benefits. A licensed provider decides whether a prescription is appropriate. Transformation Health does not accept payment from providers. How we make money.

What happens next: the research pipeline

GLP-1 for inflammation and autoimmune disease is an active area of research. Researchers continue to study GLP-1 medications in:

• Rheumatoid arthritis
• Inflammatory bowel disease
• Psoriasis
• Neurological conditions, including Parkinson’s disease and multiple sclerosis

Larger, controlled trials are what would settle these questions. If positive, they could shift the clinical picture. If negative or inconclusive, they might close off this line of inquiry, as the evoke trials did for oral semaglutide in early Alzheimer’s disease.^[4]

For now, the situation is this: the biology is interesting. The preclinical evidence is supportive. The human clinical evidence is preliminary. We are not yet at the point where GLP-1 is recommended for these conditions.

Bottom line

GLP-1 medications lowered a systemic inflammation marker (hsCRP) in the SELECT trial, though weight loss likely accounts for part of that change. Early observational data suggest possible benefit in some autoimmune conditions. The research is promising enough to justify clinical trials.

But we are not there yet. These medications are not approved for inflammation or autoimmune conditions. The evidence is not mature. The optimal dose is unknown. Long-term safety in these uses is unstudied.

If you are considering GLP-1 for these reasons, have an honest conversation with a licensed provider about what the research actually shows, what the gaps in the evidence are, and what the realistic risks and potential benefits might be for your specific situation.

Transformation Health is relaunching as an independent GLP-1 guide with a free custom report that compares programs. Leave your email to be told when the report is available.

Citations

[1] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

[2] Kellner DA, et al. “Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis.” ACR Open Rheumatology 2025;7(9):e70103. https://pubmed.ncbi.nlm.nih.gov/40932015/

[3] Colwill M, et al. “Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.” Journal of Crohn’s and Colitis 2025;19(9):jjaf167. https://pubmed.ncbi.nlm.nih.gov/40972535/

[4] Cummings JL, et al. “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.” Lancet 2026;407(10544):2167-2179. https://pubmed.ncbi.nlm.nih.gov/41865758/

[5] Ku SC, Chang HC. “Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: An updated systematic review and meta-analysis.” Journal der Deutschen Dermatologischen Gesellschaft 2024;22(8):1148-1152. https://pubmed.ncbi.nlm.nih.gov/38824670/